Translational Oncology最新文献

{"title":"LUNAR: Full Moon or Eclipse? An exploration into tumor treating fields in lung cancer","authors":"Timothée Olivier ,&nbsp;Vinay Prasad","doi":"10.1016/j.tranon.2025.102397","DOIUrl":"10.1016/j.tranon.2025.102397","url":null,"abstract":"<div><div>The LUNAR trial investigated the addition of Tumor Treating Fields (TTFs) to “standard therapy” in patients with metastatic lung cancer after at least one line of platinum-based chemotherapy. The “standard therapy” was either an anti-PD(L)1 therapy (immunotherapy) or docetaxel. The addition of TTFs provided a 3.3 months median survival gain. We raised concerns about LUNAR results internal and external validity.</div><div>First, patient selection and the control arm do not mirror current practice. Two-thirds of patients did not receive prior immunotherapy, which is standard in first-line treatment. Also, the “choice” of the “standard therapy” was restricted by drug availability, resulting in 41 % of patients not receiving immunotherapy during the trial – those allocated to receive docetaxel – had no prior exposure to immunotherapy. Some patients may have harbored actionable mutations, and did not receive targeted therapy.</div><div>Second, we raised statistical questions. The sample size was shrunk after an unplanned analysis, with unshared and unclear justifications. The decision may have been influenced by a chance deviation in data favoring the intervention. Also, as significantly more patients were censored after withdrawals in the TTFs group, informative censoring could have amplified the survival gain.</div><div>Third and last, without a sham-control design (the equivalent of placebo for devices), it's hard to isolate the impact of TTFs from the extra-attention associated with its administration (continuous 24/7 support, frequent home-based interactions).</div><div>Overall, LUNAR do not apply to clinical settings where immunotherapy and molecular testing is offered, and many factors may have artificially boosted the reported survival gain. A sham-controlled trial is needed to answer whether TTFs are beneficial.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102397"},"PeriodicalIF":5.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional roles of neutrophil extracellular traps in oral microbiota carcinogenesis: A systematic review","authors":"Jie Shen ,&nbsp;Haitao Lin ,&nbsp;Kangnan Mo ,&nbsp;Zhong Liang ,&nbsp;Yan Zhang ,&nbsp;Huatao Quan ,&nbsp;Xing Wang ,&nbsp;Chenping Zhang ,&nbsp;Chao Chen","doi":"10.1016/j.tranon.2025.102361","DOIUrl":"10.1016/j.tranon.2025.102361","url":null,"abstract":"<div><h3>Background</h3><div>Neutrophil extracellular traps (NETs) are network structures composed of DNA, histones, and antimicrobial proteins,released by activated neutrophils to trap and eliminate extracellular pathogens. Recent research has demonstrated a strong correlation between NETs and various diseases, including immune dysregulation, thrombosis, and malignancies. This review synthesizes current research on NETs, focusing on its biological role in oral squamous cell carcinoma (OSCC) and explores its potential in treating.</div></div><div><h3>Methods</h3><div>A literature review in the PubMed database was conducted to examine the impact of NETs on the homeostasis of oral microbiota and the involvement in the development of oral microbiota-related carcinogenesis.</div></div><div><h3>Results</h3><div>Various microorganisms, including <em>Porphyromonas gingivalis, Fusobacterium nucleatum, Streptococcus</em> spp., along with <em>Candida albicans</em>, as well as certain viruses such as Human papillomavirus (HPV), Human herpes virus 8 (HHV-8), and Herpes simplex virus-1 (HSV-1)are regulated by NETs during oral colonization and proliferation and have been identified as contributors to the pathogenesis of oral squamous cell carcinoma. NETs have been shown to play a dual role in the carcinogenic process of oral microbiota in humans. At the initial stage of tumor formation, NETs inhibit tumorigenesis by eliminating tumorigenic bacteria that infiltrated the tumor; however, following tumor establishment, various cytokines and chemokines that promote tumor progression are released by neutrophils during the NETs formation.</div></div><div><h3>Conclusion</h3><div>This article reviews the oncogenic mechanisms of NETs in the oral microbiota, with potential implications for early tumor detection and the development of microbe-targeted therapies.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102361"},"PeriodicalIF":5.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting FASN enhances cisplatin sensitivity via SLC7A11-mediated ferroptosis in cervical cancer","authors":"Xiaojun Wang ,&nbsp;Qiqiao Du ,&nbsp;Qiuwen Mai ,&nbsp;Qiaojian Zou ,&nbsp;Shuyi Wang ,&nbsp;Xiaoying Lin ,&nbsp;Qianrun Chen ,&nbsp;Mengxun Wei ,&nbsp;Chudan Chi ,&nbsp;Zhangqing Peng ,&nbsp;Karima Abdugheni ,&nbsp;Liu Du ,&nbsp;Yili Chen ,&nbsp;Shuzhong Yao ,&nbsp;Junxiu Liu","doi":"10.1016/j.tranon.2025.102396","DOIUrl":"10.1016/j.tranon.2025.102396","url":null,"abstract":"<div><h3>Objective</h3><div>The cisplatin resistance significantly hinders the prospects for curing patients with advanced, recurrent, and metastatic cervical cancer (CC). Our study aims to clarify the mechanisms underlying cisplatin resistance in CC and provide a novel treatment strategy to overcome the cisplatin resistance of CC patients.</div></div><div><h3>Methods</h3><div>Intracellular levels of reactive oxygen species, glutathione, malondialdehyde and Fe²⁺ were measured as indicators of ferroptosis. Biological information analyses, IC₅₀, immunofluorescence assays, qPCR and western blot analyses were conducted to elucidate the functions of FASN in CC. In vivo studies were conducted to examine the antitumor effects of the combination of TVB-2640 and cisplatin.</div></div><div><h3>Results</h3><div>Fatty acid synthase (FASN) was identified as a key driver of cisplatin resistance in CC through transcriptome sequencing and Gene Expression Omnibus (GEO) data analysis. The clinically safe FASN inhibitor TVB-2640 was found to restore cisplatin sensitivity, resulting in synergistic tumor growth attenuation in xenograft models. Mechanistically, FASN downregulation promoted ferroptosis and reduced solute carrier family 7 member 11 (SLC7A11) expression, both in vitro and in vivo models.</div></div><div><h3>Conclusion</h3><div>Targeting FASN enhances cisplatin sensitivity in CC by promoting SLC7A11-mediated ferroptosis. TVB-2640 combined with cisplatin had superior synergistic antitumor effects in cisplatin-resistant CC models.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102396"},"PeriodicalIF":5.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenteric benign lymph node enlargement in colorectal cancer: Friend or foe?","authors":"Wang Junwei ,&nbsp;Chen Xin ,&nbsp;Guo Limei ,&nbsp;Li Fei ,&nbsp;Lu Siyi ,&nbsp;Ma Yao ,&nbsp;Hsinyi Lin ,&nbsp;Shi Xiangchao ,&nbsp;Fu Wei ,&nbsp;Zhou Xin","doi":"10.1016/j.tranon.2025.102368","DOIUrl":"10.1016/j.tranon.2025.102368","url":null,"abstract":"<div><h3>Introduction</h3><div>Benign lymph node enlargement (BLNE) is common in colorectal cancer; however, few studies have investigated its influence on prognosis, clinicopathological features, and pathogenesis.</div></div><div><h3>Methods</h3><div>A cohort study was conducted to analyze the clinicopathologic features and prognosis of colorectal cancer patients, categorized based on the presence or absence of BLNE. Given the correlation between lymph nodes and immune response, immunohistochemistry, transcriptome analysis, and exon sequencing were employed to further investigate the differences in the immune microenvironment of primary tumors.</div></div><div><h3>Results</h3><div>Overall, 630 AJCC stage I/II patients were included in the study, with 131 in the BLNE group and 499 in the Non-BLNE (NBLNE) group. Patients in the BLNE group were found to have a significantly better disease-free survival (DFS) (hazard ratio [HR] 0.44, <em>P</em> = 0.016) and overall survival (OS) (HR 0.46, <em>P</em> = 0.011) than those in the NBLNE group. Pathologically, compared with the NBLNE group, the BLNE group had more mature tertiary lymphoid structures (66.7 % vs. 36.5 %, <em>P</em> = 0.002) and higher immunoscores (18.8 % vs. 2.1 %, <em>P</em> = 0.004) in primary tumor tissue. Also, transcriptome analysis showed that, compared with NBLNE, the genes upregulated in BLNE were enriched in immune-related pathways, such as adaptive immune response and immuno-regulatory interactions. Whole-exon sequencing analysis revealed a higher tumor mutation burden (TMB) in the BLNE group [6.03 (5.59, 7.59) vs. 5.33 (4.62, 6.34), <em>P</em> = 0.025].</div></div><div><h3>Conclusion</h3><div>BLNE is positively associated with the prognosis of colorectal cancer, possibly because patients with BLNE have a stronger anti-tumor immune response.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102368"},"PeriodicalIF":5.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of a novel cell line established from mice gastrointestinal stromal model by chemical induction","authors":"Zhan Zhao ,&nbsp;Shenghui Qiu ,&nbsp;Xiangwei Zhang ,&nbsp;Shijin Liu ,&nbsp;Lu Wang ,&nbsp;Hanyang Guan ,&nbsp;Jiashuai He ,&nbsp;Yangzhi Hu ,&nbsp;Xiaobo Li ,&nbsp;Simin Luo ,&nbsp;Zuyang Chen ,&nbsp;Tianmu Mo ,&nbsp;Yiran Zhang ,&nbsp;Xiaoxu Zhao ,&nbsp;Yunlong Pan ,&nbsp;Hui Ding ,&nbsp;Jie Cao ,&nbsp;Jinghua Pan","doi":"10.1016/j.tranon.2025.102388","DOIUrl":"10.1016/j.tranon.2025.102388","url":null,"abstract":"<div><h3>Background</h3><div>Gastrointestinal stromal tumors (GISTs) are a type of tumor that originates from gastrointestinal mesenchymal tissue. Although several somatic or germline mutation GIST mice were established, however, there is still a lack of an authentic mice GIST cell lines for further experimental study.</div></div><div><h3>Methods</h3><div>We developed a chemically induced C57BL/6 J GIST model using 3- methylcholanthrene. Tumor characteristics were confirmed through histology and IHC. Primary cells were isolated to establish the mGSTc01 cell line, and molecular profiling was conducted. Additionally, we established GIST model in immunocompetent mice to evaluate their sensitivity to imatinib.</div></div><div><h3>Results</h3><div>Our study successfully developed a chemically induced murine GIST model, characterized by positive staining of c-kit and DOG-1. The mGSTc01 monoclonal cell line exhibited slender morphology and expressed the c-kit marker, Whole exome sequencing uncovered mutations of Lamb1, MMP9, and c-kit in GIST cells and provided a detailed picture of the entire genome's copy number variations. RNA sequencing indicated genes associated with cell adhesion and focal adhesion were enriched in mGSTc01 cells. The mGSTc01 cells demonstrated obvious malignant behaviors, notably elevated migration, adhesion, and proliferation. In immunocompetent mice, subcutaneous xenografts not only reserved the aggressive phenotype but also displayed a response to imatinib, underscoring the model's applicability for advancing therapeutic research.</div></div><div><h3>Conclusion</h3><div>We firstly established a mGSTc01 cell line derived from C57BL/6 J mice GIST tumor offers, which closely mimicking human disease characteristics. It is a potent platform for investigating tumor microenvironment of GIST in mice model, and provides a novel way for new therapeutic discoveries in GIST.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102388"},"PeriodicalIF":5.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on estrogen receptor-positive/progesterone receptor-negative breast cancer","authors":"Zhengjia Lu,&nbsp;Tingrui Wang,&nbsp;Lu Wang,&nbsp;Jia Ming","doi":"10.1016/j.tranon.2025.102387","DOIUrl":"10.1016/j.tranon.2025.102387","url":null,"abstract":"<div><div>Breast cancer, which arises from the epithelial tissue of the breast, is one of the most common cancers affecting women worldwide. Its incidence and mortality rates have been increasing in both developed and developing countries. As a hormone-dependent cancer, breast cancer is classified into several molecular subtypes based on the expression of key markers: Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER-2), and Ki67. PR loss is associated with endocrine resistance and a poorer prognosis in breast cancer. Despite this, the underlying mechanisms of ER-positive/PR-negative (ER+PR-) breast cancer remain poorly understood. This study aims to review recent advancements in research on ER+PR- breast cancer, analyze its clinical characteristics and molecular mechanisms, and provide recommendations for more targeted therapeutic approaches.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new dawn: Vitalising translational oncology research in Africa with the help of advanced cell culture models","authors":"Stefanie Klima ,&nbsp;Tracey Hurrell ,&nbsp;Mubeen Goolam ,&nbsp;Chrisna Gouws ,&nbsp;Anna-Mart Engelbrecht ,&nbsp;Mandeep Kaur ,&nbsp;Iman van den Bout","doi":"10.1016/j.tranon.2025.102391","DOIUrl":"10.1016/j.tranon.2025.102391","url":null,"abstract":"<div><div>The advent of in vitro models such as induced pluripotent stem cells (iPSC) and patient derived (disease) organoids is supporting the development of population and patient specific model systems reflecting human physiology and disease. However, there remains a significant underrepresentation of non-European, especially African model systems. The development of such models should be enthusiastically embraced by Sub-Saharan African countries (SSAC) and middle-income countries (LIMC) to direct their own research focused on the improvement of health of their own populations at a sustainable cost within their respective funding environments. Great care needs to be taken to develop national frameworks to direct, sustainably fund and support such efforts in a way that maximises the output of such models for the investment required. Here, we highlight how advanced culture models can play a role in vitalising local healthcare research by focusing on locally relevant health care questions using appropriate cell culture models. We also provide a potential national platform example that could maximise such output at the lowest cost. This framework presents an opportunity for SSAC and LMIC to base their healthcare research on locally relevant models to ensure that developed health care initiatives and interventions are best suited for the populations they serve and thus represent a reset in global health care research at large.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102391"},"PeriodicalIF":5.0,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143824284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptomics of HERVs reveals clinico-biological characterization of LTR5_Hs and HERVS71 loci in gastric cancer","authors":"Juan Xu ,&nbsp;Jie Liu ,&nbsp;Yanhuan Wang ,&nbsp;Linjie Peng ,&nbsp;Wang Li ,&nbsp;Likai Ji ,&nbsp;Yang Yang ,&nbsp;Benshuai You ,&nbsp;Yan Huang ,&nbsp;Shikun Fang ,&nbsp;Ping Ni ,&nbsp;Wen Zhang ,&nbsp;Chenglin Zhou","doi":"10.1016/j.tranon.2025.102369","DOIUrl":"10.1016/j.tranon.2025.102369","url":null,"abstract":"<div><div>Human endogenous retroviruses (HERVs), a type of endogenous transposable elements (ETE), have emerged as potential biomarkers and therapeutic targets for cancers. However, the transcriptional relevance of HERV elements in gastric cancer (GC) remains largely unexplored. This study aims to elucidate the interactions between locus-specific HERVs expression and clinical dynamics in GC patients. We compared HERVs locus-specific expression profiles from RNA sequencing of tumor and adjacent tissues, validated using the GEO database and RT-PCR. Analysis of dysregulated ETEs revealed 113 upregulated and 46 downregulated ETEs in tumor tissues compared to adjacent non-tumor tissues. Significant differences were found in HERVs clades such as HERVK, HERVS71, and HERVH. Four clinically relevant HERV elements—LTR5_Hs_1q22 and HERVS71_19q13.22 (int, rve, RNase_H)—were validated in serum samples via RT-PCR. Higher HERVs expression (HERVs^high) correlated with larger tumor size, higher grade, increased lymph node metastasis, and higher Odds ratio compared to lower expression (HERVs^low) groups. The diagnostic performance of the four HERV elements surpassed that of conventional biomarkers and improved with combined biomarker analysis. Differential and functional analysis indicated that these HERV elements significantly impacted the cell cycle, with their upregulation linked to tumor growth both in vitro and in vivo. Our exploration demonstrates the clinical significance of HERVs in tumor progression, highlighting their functional role and providing a valuable resource for developing new biomarkers and therapeutic targets in GC.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102369"},"PeriodicalIF":5.0,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143824285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"circHIPK2 promotes malignant progression of laryngeal squamous cell carcinoma through the miR-889-3p/MCTS1/IL-6 axis","authors":"Yang-Guang Sun ,&nbsp;Zhen-Kun Yu ,&nbsp;Xi Chen ,&nbsp;Si-Yao Zhang ,&nbsp;Wan-Juan Wu ,&nbsp;Kai Liu ,&nbsp;Lei Cheng","doi":"10.1016/j.tranon.2025.102390","DOIUrl":"10.1016/j.tranon.2025.102390","url":null,"abstract":"<div><div>Laryngeal squamous cell carcinoma (LSCC) is a common malignant tumor of the head and neck with a poor prognosis. The role of circRNAs in LSCC remains largely unknown. In this study, quantitative real-time PCR (qRT-PCR), Sanger sequencing and fluorescence in situ hybridization were undertaken to detect the expression, localization, and clinical significance of circHIPK2 in LSCC tissues and TU686 and TU212 cells. The functions of circHIPK2 in LSCC were explored through proliferation analysis, EdU staining, colony formation assay, wound healing assay, and Transwell assay. The regulatory mechanisms underpinning circHIPK2, miR-889–3p, and MCTS1 were investigated using luciferase assay, Western blotting, and qRT-PCR. We found that LSCC tissues and cells demonstrated high expression of circHIPK2 that was closely associated with the malignant progression and poor prognosis of LSCC. Knockdown of circHIPK2 inhibited the proliferation and migration of LSCC cells in vitro. Mechanistic studies showed that circHIPK2 competitively bound to miR-889–3p, elevated MCTS1 level, promoted IL-6 secretion, and ultimately accelerated the malignant progression of LSCC. In conclusion, an axis involving circHIPK2, miR-889–3p, MCTS1 and IL-6 regulates the malignant progression of LSCC. circHIPK2 expression may serve as a novel diagnostic and prognostic biomarker for LSCC.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102390"},"PeriodicalIF":5.0,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancement of Prognostic Outcomes in Stage III Non-Small Cell Lung Cancer: A Retrospective Study on Neoadjuvant Immuno-Chemotherapy Followed by Definitive Chemo-Radiotherapy","authors":"Wenxin Ding ,&nbsp;Yechen Ma ,&nbsp;Hao Hu ,&nbsp;Tian Xu ,&nbsp;Hexin Duan ,&nbsp;Jiang Liang ,&nbsp;Weiwei Liang ,&nbsp;Hao Zhou ,&nbsp;Xi Zhang ,&nbsp;Zewen Song","doi":"10.1016/j.tranon.2025.102394","DOIUrl":"10.1016/j.tranon.2025.102394","url":null,"abstract":"<div><h3>Background</h3><div>The effectiveness of neoadjuvant immuno-chemotherapy in stage III non-small cell lung cancer (NSCLC) patients undergoing definitive concurrent/sequential chemo-radiotherapy (CRT) is not well established.</div></div><div><h3>Methods</h3><div>This retrospective study involved stage III NSCLC patients treated at the Third Xiangya Hospital and Xiangxi Autonomous Prefecture People's Hospital. We compared prognosis, dosimetric outcomes, and radiation pneumonitis incidence between those receiving neoadjuvant immuno-chemotherapy and those undergoing immunotherapy maintenance after CRT. Tumor assessments were conducted on patients administered 2–4 cycles of immuno-chemotherapy, and diagnostic CT images of 54 patients were analyzed for treatment impact.</div></div><div><h3>Results</h3><div>A total of 76 patients received neoadjuvant immuno-chemotherapy followed by CRT, while 68 received immunotherapy after CRT. The median progression-free survival (PFS) for the neoadjuvant group was 29.3 months compared to 13.4 months for the maintenance group (<em>p</em> &lt; 0.001). Median overall survival (OS) was not reached for the neoadjuvant group, while it was 37.4 months for the maintenance group (<em>p</em> = 0.004). Uni-variable analysis indicated neoadjuvant immuno-chemotherapy as an independent OS prognostic factor. The disease control rate was 99.09 %, and significant reductions in tumor volume and radiation doses to healthy tissues were observed post-treatment.</div></div><div><h3>Conclusion</h3><div>Our findings suggest neoadjuvant immuno-chemotherapy improves prognosis for stage III NSCLC patients and effectively reduces tumor volume and organ-at-risk radiation exposure, warranting further phase III trials.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"56 ","pages":"Article 102394"},"PeriodicalIF":5.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}